ClinicalTrials.gg
CompletedNCT07220629RESOLVE-2Updated Oct 27, 2026

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

A Phase 2 interventional study of NT-0796 and Placebo in Obesity, sponsored by Rezera (formerly NodThera Limited). Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Rezera (formerly NodThera Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.

Read the detailed description

Potential participants will be screened within 28 days prior to baseline (Day 1), and eligible participants will be randomly assigned to receive the Investigational Medicinal Product (IMP, either NT-0796 or placebo) twice daily (BID). All participants will receive sc semaglutide. The IMP will be administered orally. Semaglutide will be initiated and titrated using a fixed, 4-weekly dose escalation scheme, as per the approved USPI.

Following 32 weeks of active treatment, participants will enter a 4-week safety follow-up period before being discharged from the study. Semaglutide will be provided for the period from baseline (Day 1) up until completion of the 4-week safety follow-up.

The Primary Endpoint of the study will be the safety and tolerability of NT-0796 as an adjunct to semaglutide, the key secondary endpoint will be the effect of NT-0796 as an adjunct to semaglutide on weight loss while secondary endpoints include percentage weight change from baseline.

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • RESOLVE -2
  • Obesity
  • NLRP3
  • NT-0796
  • Rezera Inc.
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 82 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Rezera (formerly NodThera Limited) is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 to 75 years (inclusive) at Screening who have signed and are willing and able to comply with the study protocol.
  2. Have a of ≥30.0 kg/m2 and \<45.0 kg/m2 at Screening. (BMI values should be calculated to one decimal point precision and then assessed in terms of the required range).
  3. History of at least one self-reported unsuccessful dietary effort to lose body weight.
  4. Meeting requirements for, and intending to start, treatment with sc semaglutide, as per the approved USPI.

Exclusion criteria

Exclusion Criteria:

  1. Exposure to incretins, irrespective of the indication, within the 12 months prior to Screening.
  2. Known to semaglutide or any of its , or previous inability to tolerate semaglutide.
  3. Type 1 or Type 2 Diabetes Mellitus (T1DM or T2DM), and/or ≥6.5% (48 mmol/mol) at Screening and/or use of any anti-diabetic medications.
  4. History of stroke with residual neurological deficit within 2 years or within 6 months prior to Day 1.
  5. History of acute coronary syndrome (ACS) including unstable angina, acute myocardial infarction (both ST segment elevation and non-ST segment elevation) within 6 months prior to Day 1.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Twice daily orally administered NT-0796 capsule

    Participants will receive study medication twice daily orally for up to 32 weeks, containing NT-0796 twice daily

    Drug: NT-0796

  • Placebo comparator
    Placebo orally administered capsule

    Participants will receive placebo twice daily orally for up to 32 weeks

    Drug: Placebo

Interventions

  • Orally administered capsules

  • DrugPlacebo

    Orally administered capsules

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Assess the safety and tolerability of NT-0796 as an adjunct to semaglutide in participants with obesity by assessing AEs and SAEs, symptoms of nausea and vomiting, clinical laboratory parameters, vital signs and ECGs.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Ratio change from baseline to Week 20 in hsCRP

    Time frame: Baseline to Week 20

  2. Ratio change from baseline to Week 20 in Fibrinogen

    Time frame: Baseline to Week 20

  3. Percent change in body weight in participants with obesity

    Time frame: Baseline to Week 20

  4. Ratio change from baseline in hsCRP (mg/L)

    Time frame: Weeks 4, 8, 12, 16, 24, 28, 32 and 36

  5. Time-averaged ratio change from baseline in hsCRP (mg/L)

    Time frame: Between weeks 4 and 32.

  6. Time-to- achievement of hsCRP (mg/L) < 2, in the subset of subjects > 2 at baseline

    Time frame: Baseline to Week 32

  7. Ratio change from baseline in fibrinogen (mg/dL)

    Time frame: Weeks 4, 8, 12, 16, 24, 28, 32 and 36

  8. Percent change in body weight in participants with obesity

    Time frame: Baseline to Weeks 4, 8, 12, 16, 24, 28, 32, 36

  9. Change in waist circumference and waist/height ratio

    Time frame: Baseline to Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36

  10. Proportion of participants that achieve a body weight reduction of ≥5%, ≥10% or ≥15%

    Time frame: Baseline to Week 4, 8, 12, 16, 20, 24, 28, 32, 36

  11. NT-0796/NDT-19795 concentrations in plasma

    Time frame: Baseline to Week 24

07

Study locations

9 sites
  • Investigative Site
    Mesa, Arizona 85225, United States
  • Investigative Site
    Hialeah, Florida 33016, United States
  • Investigative Site
    Jacksonville, Florida 32216, United States
  • Investigative Site
    Miami, Florida 33147, United States
  • Investigative Site
    Marrero, Louisiana 70006, United States
  • Investigative Site
    Columbus, Ohio 43213, United States
  • Investigative Site
    Seabrook, Texas 77586, United States
  • Investigative Site
    Salt Lake City, Utah 84124, United States
  • Investigative Site
    Manassas, Virginia 20110, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Aug 2026, 10 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Oct 24, 2025
StartActual
Oct 2, 2025
Primary completionActual
Aug 21, 2026
CompletionActual
Aug 21, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07220629
Lead sponsor
Rezera (formerly NodThera Limited)
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Oct 2, 2025
Primary completion
Aug 21, 2026
Completion
Aug 21, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruvonoflast

Start the discussion